[肺血管干预:通过适应创新,通过差异化进步]
1Department of Pulmonary and Critical Care Medicine, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China.
像BPA和支架这样的肺血管干预提供了对肺高血压和动脉狭窄的最小侵入性治疗方法. 未来的创新旨在将其确立为核心疗法,改善患者的治疗结果.
科学领域:
- 心脏病学 心脏病学
- 干预性肺病学 干预性肺病学
- 医疗技术 医疗技术 医学技术
背景情况:
- 肺血管疾病需要有效的治疗选择.
- 最少侵入性技术正在推进医学干预.
- 现有的冠状动脉干预技术需要适应肺循环.
研究的目的:
- 审查肺血管干预技术的进展.
- 为突出BPA,支架和肺血管疾病的PADN等技术.
- 讨论未来的方向和这些干预措施的潜力.
主要方法:
- 审查当前的肺血管干预技术.
- 与冠状动脉干预 (PCI) 原则进行比较.
- 对肺循环的挑战和修改进行分析.
- 探索新兴技术和未来的研究.
主要成果:
- 肺血管干预,包括气球肺血管整形 (BPA),肺动脉支架和皮肤肺动脉缩 (PADN),显示出显著的希望.
- 这些技术改善了慢性血栓栓塞性肺高血压 (CTEPH),肺动脉狭窄和肺动脉高血压 (PAH) 的预后.
- 适应是必要的,以管理肺血管的低压,薄壁性质,并减轻诸如穿孔和血栓形成等风险.
结论:
- 肺血管干预技术是一个快速发展的领域,具有最小侵入性的优势.
- 进一步发展仪器,成像,人工智能和分子疗法至关重要.
- 这些创新可以将肺血管干预从辅助升级为核心治疗.
更多相关视频
05:31Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model
Published on: June 8, 2022
13:48Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound
Published on: April 21, 2023
相关概念视频
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Mechanical Ventilation III: Noninvasive Ventilation
Noninvasive Positive-Pressure Ventilation...
